KCA-1490

KCA-1490 is a dual PDE3/4 inhibitor with IC50 values of 369 nM and 42 nM, respectively. KCA-1490 exhibits potent bronchodilatory and anti-inflammatory activity. KCA-1490 suppresses Histamine (HY-B1204) -induced bronchoconstriction in vivo, which is promising for research of asthma and chronic obstructive pulmonary disease (COPD) [1][2][3].

Product Specifications

CAS Number

[909719-71-7]

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/kca-1490.html

Smiles

O=C1CC(C)C(C2=CC=C(OC)N3C2=CC(C(F)(F)F)=N3)=NN1

Molecular Formula

C14H13F3N4O2

Molecular Weight

326.27

References & Citations

[1]Ochiai K, et al. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. Bioorg Med Chem Lett. 2012 Sep 15;22 (18) :5833-8.|[2]Ochiai K, et al. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett. 2013 Jan 1;23 (1) :375-81.|[3]Jin J, et al. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. Int J Mol Sci. 2023 Jul 15;24 (14) :11518.